Blogs about: Ascentar
Featured Blog
ASCENT-2 Novacea Study Halted
Novacea, Inc. (NASDAQ: NOVC) announced on 11/5/07 that the company has ended its Phase 3 ASCENT-2 clinical trial of Asentar(TM) (DN-101), the company’s lead investigational cancer therapy for th… more →
Center for Oncology Research & Treatment--Dallas, TX
ASCENT-2 Novacea Study Halted
bmirtsching wrote 2 years ago: Novacea, Inc. (NASDAQ: NOVC) announced on 11/5/07 that the company has ended its Phase 3 ASCENT-2 cl … more →
DN-101 (Ascentar) for Hormone-Refractory Prostate Cancer
— 2 comments
bmirtsching wrote 2 years ago: DN-101 (Ascentar) is a high-dose formulation of the active form of vitamin D. Vitamin D, once though … more →
